Faculty of 1000 Biology | Faculty member: Richard Simon

6-Jul-2008

	Richard Simon Biometric Research Branch, National Cancer Institute, Bethesda, United States of America
	Faculty Member: PHARMACOLOGY & DRUG DISCOVERY > Cancer therapeutics [ since 18 August 2006 ]

email [Help]

Evaluations

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
Amado RG, Wolf M, …, Patterson SD, Chang DD
J Clin Oncol 2008 Apr 1 26(10):1626-34 [abstract on PubMed] [related articles] [full text] [order article]

Selected by | Richard Simon
Evaluated 14 May 2008

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Gennari A, Sormani MP, …, Pfeffer U, Bruzzi P
J Natl Cancer Inst 2008 Jan 2 100(1):14-20 [abstract on PubMed] [related articles] [full text] [order article]

Selected by | Richard Simon
Evaluated 13 Feb 2008

Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.
Lewis IJ, Nooij MA, …, MRC BO06 and EORTC 80931 collaborators, European Osteosarcoma Intergroup
J Natl Cancer Inst 2007 Jan 17 99(2):112-28 [abstract on PubMed] [related articles] [full text] [order article]

Selected by | Richard Simon
Evaluated 23 Apr 2007

Concordance among gene-expression-based predictors for breast cancer.
Fan C, Oh DS, …, van't Veer LJ, Perou CM
N Engl J Med 2006 Aug 10 355(6):560-9 [abstract on PubMed] [related articles] [FREE full text]

Selected by | Richard Simon
Evaluated 12 Oct 2006